Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Eigentler

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 12, 2024
Second opinion and self-efficacy in German skin cancer patientsHenner Stege, Sara Schneider, Andrea Forschner, et al.
International Journal of Computer Assisted Radiology and Surgery|May 30, 2024
Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflowAlessa Hering, Max Westphal, Annika Gerken, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2011
Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial)Susanne Ziefle, Friederike Egberts, Sarah Heinze, et al.
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 23, 2019
S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Journal for Immunotherapy of Cancer|July 14, 2019
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker studyAndrea Forschner, Florian Battke, Dirk Hadaschik, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 7, 2019
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Klinische Padiatrie|October 11, 2017
Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP)Sonja Offenmueller, Ulrike Leiter, Benedikt Bernbeck, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 12, 2024
Second opinion and self-efficacy in German skin cancer patientsHenner Stege, Sara Schneider, Andrea Forschner, et al.
International Journal of Computer Assisted Radiology and Surgery|May 30, 2024
Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflowAlessa Hering, Max Westphal, Annika Gerken, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 19, 2011
Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial)Susanne Ziefle, Friederike Egberts, Sarah Heinze, et al.
Frontiers in Oncology|March 18, 2021
Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant MelanomaAndrea Forschner, Tobias Sinnberg, Gabi Mroz, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 23, 2019
S2k-Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) - Update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Journal for Immunotherapy of Cancer|July 14, 2019
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker studyAndrea Forschner, Florian Battke, Dirk Hadaschik, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 7, 2019
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018Jürgen C Becker, Thomas Eigentler, Bernhard Frerich, et al.
Klinische Padiatrie|October 11, 2017
Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP)Sonja Offenmueller, Ulrike Leiter, Benedikt Bernbeck, et al.
Pageof 13